Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0425 | Nilutamide

Molecular Formula C12H10F3N3O4
Molecular Weight 317.22
Structure
State solid
Route of elimination Nilutamide is extensively metabolized andless than 2% of the drug is excreted unchanged in urine after 5 days. Fecal elimination is negligible, ranging from 1.4% to 7% of the dose after 4 to 5 days.
Half life 38.0-59.1 hours
Absorption Rapidly and completely absorbed, yielding high and persistent plasma concentrations.
Trade names Nilandron and Anandron
Description nonsteroidal antiandrogen (NSAA)

L

L02BB02 Nilutamide


[L02BB] Anti-androgens


[L02B] HORMONE ANTAGONISTS AND RELATED AGENTS


[L02] ENDOCRINE THERAPY


[L] Antineoplastic and immunomodulating agents

Toxicity Dose Time Species Model Method Action Positive criterion Reference
OXYGEN CONSUMPTION RATE (OCR) 66 μM 2 minutes human HepG2 Measurement of OCR decrease EC50 7
ECAR 79 μM 2 minutes human HepG2 Measurement of ECAR increase EC50 7
GLUCOSE GALACTOSE IC50 RATIO 300.0 ± 0, 300.0 ± 0, 1, 300.0 ± 0, 272.5 ± 21.0, 1.1 4hr H9c2 cells high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). Negative glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) 50
GLUCOSE GALACTOSE IC50 RATIO 250 ± 86.6, 44.0 ± 12.0 , 5.7 , 300.0 ± 0, 15.6 ± 9.9 , 19.2 24hr H9c2 cells high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) 50

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 40 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]


H360 (97.5%): May damage fertility or the unborn child [Danger Reproductive toxicity]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P201, P202, P264, P270, P281, P301+P310, P308+P313, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)


  • 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione 1-(3'-trifluoromethyl-4'-nitrophenyl)4,4-dimethyl-imidazoline-2,5-dione
    1-(3'-trifluoromethyl-4'nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione 1-(3'trifluoromethyl-4'-nitropheyl)-4,4-dimethyl-imidazoline-2,5-dione 1-(3-'trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione
    1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl imidazolidine-2,5-dione 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl-imidazolidine-2,5-dione 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl-imidazoline-2,5-dione
    1-(3-trifluoromethyl-4-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione 2,4-IMIDAZOLIDINEDIONE, 5,5-DIMETHYL-3-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)- 2,4-Imidazolidinedione,5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-
    3-(3-(trifluoromethyl)-4-nitrophenyl)-5,5-dimethylimidazolidine-2,4-dione 4CA-0906 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)-phenyl)imidazolidine-2,4-dione
    5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione
    5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1,3-diazolidine-2,4-dione
    5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-imidazolidine-2,4-dione 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione 51G6I8B902
    612N500 63612-50-0 A834440
    AB00053180 AB00053180_07 AB0013969
    AC-5260 AK-82300 AKOS005565152
    AKOS025147305 ANW-58327 AS-14123
    Anandron BCP26617 BCP9000990
    BCPP000148 BDBM50135912 BIDD:GT0683
    BIDD:PXR0177 BPBio1_000920 BRD-K23566484-001-05-2
    BRD-K23566484-001-09-4 BRN 0841906 BSPBio_000836
    BSPBio_003325 C08164 C12H10F3N3O4
    CAS-63612-50-0 CCG-39427 CHEBI:7573
    CHEMBL1274 CS-0007719 CTK8B7740
    D00965 DB00665 DSSTox_CID_14165
    DSSTox_GSID_34165 DSSTox_RID_79118 DTXSID3034165
    DivK1c_006998 EU-0100879 FT-0080574
    FT-0630740 GTPL2864 HMS1570J18
    HMS1922F03 HMS2093A10 HMS2097J18
    HMS2230E03 HMS3262P19 HMS3268C18
    HMS3369I02 HMS3414N15 HMS3678N13
    HMS3714J18 HY-13702 KBio1_001942
    KBio2_002105 KBio2_004673 KBio2_007241
    KBio3_002545 KBioGR_001100 KBioSS_002105
    L000759 LP00879 LS-79181
    Lopac-N-8534 Lopac0_000879 MCULE-3215206804
    MFCD00864670 MLS002154066 N 8534
    NCGC00015754-01 NCGC00015754-02 NCGC00015754-03
    NCGC00015754-04 NCGC00015754-05 NCGC00015754-06
    NCGC00015754-07 NCGC00015754-08 NCGC00015754-09
    NCGC00015754-10 NCGC00015754-11 NCGC00015754-12
    NCGC00015754-15 NCGC00015754-16 NCGC00025280-01
    NCGC00025280-02 NCGC00025280-03 NCGC00025280-04
    NCGC00025280-05 NCGC00025280-06 NCGC00025280-07
    NCGC00025280-08 NCGC00255271-01 NCGC00261564-01
    NSC-758683 NSC758683 Nilandron
    Nilandron (TN) Nilandrone Nilutamida
    Nilutamida [Spanish] Nilutamide (USAN/INN) Nilutamide [USAN:INN:BAN]
    Nilutamide, European Pharmacopoeia (EP) Reference Standard Nilutamide, solid Nilutamidum
    Nilutamidum [Latin] Pharmakon1600-01504152 Prestwick0_000928
    Prestwick1_000928 Prestwick2_000928 Prestwick3_000928
    PubChem19359 Q3877030 RU 23908
    RU 23908-10 RU-23908 RU-23908;RU 23908;RU23908
    RU23908 SB19036 SBB067297
    SBI-0050854.P003 SC-74493 SCHEMBL12670
    SMR001233381 SPBio_002125 SPBio_003015
    SPECTRUM1504152 SR-01000076034 SR-01000076034-1
    SR-01000076034-3 SR-01000076034-5 SR-01000076034-6
    SR-01000076034-9 ST075550 STK633161
    SpecPlus_000902 Spectrum2_001973 Spectrum3_001633
    Spectrum4_000600 Spectrum5_001512 Spectrum_001625
    TC-030602 Tocris-1759 Tox21 110213
    Tox21_110213 Tox21_110213_1 Tox21_301589
    Tox21_500879 UNII-51G6I8B902 XWXYUMMDTVBTOU-UHFFFAOYSA-N
    Z2417927201 ZINC3874498 nilutamide

    DrugBank Name Nilutamide
    DrugBank DB00665
    CAS Number 63612-50-0
    PubChem Compound 4493
    KEGG Compound ID C08164
    KEGG Drug D00965
    PubChem.Substance 46505381
    ChEBI 7573
    PharmGKB PA450632
    ChemSpider 4337
    BindingDB 50135912.0
    TTD DAP000302
    Wikipedia Nilutamide